Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Cytokinetics, Inc. (CYTK) Insider Trading Activity
Healthcare • Biotechnology • 423 employees
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Total Value
-$5,307,712.37
Total Shares
560
Average Trade Value
-$79,219.59
Most Active Insider
Blum Robert I
Total Activity: $2,942,773
Largest Single Transaction
$1,080,750
by Blum Robert I on Mar 5, 2025
30-Day Activity
4 Transactions
Volume: 25,900 shares
Value: $1,182,800
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
President CEO
Director, Officer
|
Mar 5, 2025 | 25,000 | $1,080,750 | 381,151 (-6.6%) | Sale | |
|
EVP Research Development
Officer
|
Mar 4, 2025 | 2,000 | $85,000 | 116,071 (-1.7%) | Sale | |
|
Director
|
Mar 4, 2025 | 900 | $38,250 | 15,108 (-6.0%) | Sale | |
|
EVP Research Development
Officer
|
Mar 4, 2025 | 2,000 | $21,200 | 118,071 (+1.7%) | Exercise/Conversion | |
|
President CEO
Director, Officer
|
Mar 3, 2025 | 8,743 | $374,900 | 406,151 (-2.2%) | Sale | |
|
Evp, Chief Commercial Officer
Officer
|
Mar 3, 2025 | 1,114 | $47,768 | 67,775 (-1.6%) | Sale | |
|
EVP Research Development
Officer
|
Mar 3, 2025 | 2,449 | $105,013 | 113,622 (-2.2%) | Sale | |
|
EVP Research Development
Officer
|
Feb 18, 2025 | 2,000 | $91,960 | 116,071 (-1.7%) | Sale | |
|
EVP Research Development
Officer
|
Feb 18, 2025 | 2,000 | $21,200 | 118,071 (+1.7%) | Exercise/Conversion | |
|
EVP Research Development
Officer
|
Feb 4, 2025 | 2,000 | $21,200 | 118,071 (+1.7%) | Exercise/Conversion | |
|
EVP Research Development
Officer
|
Feb 4, 2025 | 2,000 | $96,120 | 116,071 (-1.7%) | Sale | |
|
EVP Research Development
Officer
|
Jan 21, 2025 | 2,000 | $21,200 | 118,071 (+1.7%) | Exercise/Conversion | |
|
EVP Research Development
Officer
|
Jan 21, 2025 | 2,000 | $91,840 | 116,071 (-1.7%) | Sale | |
|
EVP Research Development
Officer
|
Jan 7, 2025 | 2,000 | $98,640 | 116,071 (-1.7%) | Sale | |
|
EVP Research Development
Officer
|
Jan 7, 2025 | 2,000 | $21,200 | 118,071 (+1.7%) | Exercise/Conversion | |
|
Director
|
Jan 2, 2025 | 434 | $21,236 | 48,987 (+0.9%) | Grant | |
|
Director
|
Jan 2, 2025 | 255 | $12,477 | 25,637 (+1.0%) | Grant | |
|
Director
|
Jan 2, 2025 | 255 | $12,477 | 16,008 (+1.6%) | Grant | |
|
Director
|
Jan 2, 2025 | 127 | $6,214 | 24,686 (+0.5%) | Grant | |
|
Director
|
Jan 2, 2025 | 127 | $6,214 | 23,115 (+0.5%) | Grant | |
|
Director
|
Dec 16, 2024 | 742 | $5,469 | 25,301 (+2.9%) | Exercise/Conversion | |
|
Director
|
Dec 16, 2024 | 742 | $36,069 | 24,559 (-3.0%) | Sale | |
|
Director
|
Dec 11, 2024 | 1,780 | $89,748 | 38,461 (-4.6%) | Sale | |
|
Director
|
Dec 11, 2024 | 10,092 | $74,378 | 48,553 (+20.8%) | Exercise/Conversion | |
|
Director
|
Dec 11, 2024 | 1,780 | $13,119 | 40,241 (+4.4%) | Exercise/Conversion | |
|
EVP Research Development
Officer
|
Dec 10, 2024 | 2,000 | $101,300 | 116,071 (-1.7%) | Sale | |
|
EVP Research Development
Officer
|
Dec 10, 2024 | 5,300 | $268,339 | 118,071 (-4.5%) | Sale | |
|
EVP Research Development
Officer
|
Dec 10, 2024 | 5,300 | $42,188 | 123,371 (+4.3%) | Exercise/Conversion | |
|
EVP Research Development
Officer
|
Dec 3, 2024 | 2,028 | $104,462 | 114,071 (-1.8%) | Payment of Exercise Price | |
|
President CEO
Director, Officer
|
Dec 3, 2024 | 5,843 | $300,973 | 403,364 (-1.4%) | Payment of Exercise Price | |
|
President CEO
Director, Officer
|
Dec 3, 2024 | 11,530 | $0 | 414,894 (+2.8%) | Grant | |
|
President CEO
Director, Officer
|
Dec 3, 2024 | 11,529 | $10,000 | 409,207 (+2.8%) | Grant | |
|
Evp, Chief Financial Officer
Officer
|
Dec 3, 2024 | 4,303 | $10,000 | 38,987 (+11.0%) | Grant | |
|
Evp, Chief Financial Officer
Officer
|
Dec 3, 2024 | 1,536 | $79,119 | 37,451 (-4.1%) | Payment of Exercise Price | |
|
EVP Research Development
Officer
|
Dec 3, 2024 | 4,000 | $10,000 | 116,099 (+3.4%) | Grant | |
|
Evp, Chief Financial Officer
Officer
|
Dec 3, 2024 | 4,304 | $0 | 41,755 (+10.3%) | Grant | |
|
Evp, Chief Commercial Officer
Officer
|
Dec 3, 2024 | 1,351 | $69,590 | 65,712 (-2.1%) | Payment of Exercise Price | |
|
Evp, Chief Commercial Officer
Officer
|
Dec 3, 2024 | 3,176 | $10,000 | 67,063 (+4.7%) | Grant | |
|
Evp, Chief Commercial Officer
Officer
|
Dec 3, 2024 | 3,177 | $0 | 68,889 (+4.6%) | Grant | |
|
EVP Research Development
Officer
|
Dec 3, 2024 | 4,000 | $0 | 118,071 (+3.4%) | Grant | |
|
Vp, Chief Accounting Officer
Officer
|
Dec 3, 2024 | 764 | $10,000 | 18,162 (+4.2%) | Grant | |
|
Vp, Chief Accounting Officer
Officer
|
Dec 3, 2024 | 766 | $0 | 18,655 (+4.1%) | Grant | |
|
Vp, Chief Accounting Officer
Officer
|
Dec 3, 2024 | 273 | $14,062 | 17,889 (-1.5%) | Payment of Exercise Price | |
|
President CEO
Director, Officer
|
Dec 2, 2024 | 5,000 | $33,350 | 402,678 (+1.2%) | Exercise/Conversion | |
|
President CEO
Director, Officer
|
Dec 2, 2024 | 5,000 | $253,800 | 397,678 (-1.3%) | Sale | |
|
EVP Research Development
Officer
|
Nov 26, 2024 | 5,300 | $42,188 | 119,178 (+4.4%) | Exercise/Conversion | |
|
EVP Research Development
Officer
|
Nov 26, 2024 | 2,000 | $100,280 | 111,878 (-1.8%) | Sale | |
|
EVP Research Development
Officer
|
Nov 26, 2024 | 5,300 | $265,901 | 113,878 (-4.7%) | Sale | |
|
Director
|
Nov 25, 2024 | 742 | $37,100 | 24,559 (-3.0%) | Sale | |
|
Director
|
Nov 25, 2024 | 742 | $5,469 | 25,301 (+2.9%) | Exercise/Conversion | |
|
President CEO
Director, Officer
|
Nov 18, 2024 | 5,000 | $33,350 | 402,456 (+1.2%) | Exercise/Conversion | |
|
President CEO
Director, Officer
|
Nov 18, 2024 | 5,000 | $252,750 | 397,456 (-1.3%) | Sale | |
|
EVP Research Development
Officer
|
Nov 12, 2024 | 5,300 | $42,188 | 120,220 (+4.4%) | Exercise/Conversion | |
|
EVP Research Development
Officer
|
Nov 12, 2024 | 5,300 | $309,944 | 114,920 (-4.6%) | Sale | |
|
EVP Research Development
Officer
|
Nov 12, 2024 | 1,042 | $60,936 | 113,878 (-0.9%) | Sale | |
|
President CEO
Director, Officer
|
Nov 1, 2024 | 5,000 | $33,350 | 402,456 (+1.2%) | Exercise/Conversion | |
|
President CEO
Director, Officer
|
Nov 1, 2024 | 5,000 | $258,150 | 397,456 (-1.3%) | Sale | |
|
EVP Research Development
Officer
|
Oct 30, 2024 | 5,300 | $275,070 | 116,920 (-4.5%) | Sale | |
|
EVP Research Development
Officer
|
Oct 30, 2024 | 2,000 | $103,860 | 114,920 (-1.7%) | Sale | |
|
EVP Research Development
Officer
|
Oct 30, 2024 | 5,300 | $42,188 | 122,220 (+4.3%) | Exercise/Conversion | |
|
Director
|
Oct 28, 2024 | 4,452 | $232,617 | 24,559 (-18.1%) | Sale | |
|
Director
|
Oct 28, 2024 | 4,452 | $32,811 | 29,011 (+15.3%) | Exercise/Conversion | |
|
EVP Research Development
Officer
|
Oct 15, 2024 | 2,000 | $108,400 | 116,920 (-1.7%) | Sale | |
|
EVP Research Development
Officer
|
Oct 15, 2024 | 5,300 | $42,188 | 124,220 (+4.3%) | Exercise/Conversion | |
|
EVP Research Development
Officer
|
Oct 15, 2024 | 5,300 | $287,154 | 118,920 (-4.5%) | Sale | |
|
President CEO
Director, Officer
|
Oct 9, 2024 | 5,000 | $33,350 | 402,456 (+1.2%) | Exercise/Conversion | |
|
President CEO
Director, Officer
|
Oct 9, 2024 | 5,000 | $278,050 | 397,456 (-1.3%) | Sale |